Cardiovascular events · patients with hypertension
RAS inhibitors may leads to lower total cardiovascular events compared with beta‐blockers (low certainty).
1 finding from 1 review
Heart failure · patients with hypertension
RAS inhibitors showed no clear difference in total heart failure compared with beta‐blockers (low certainty).
1 finding from 1 review
Myocardial infarction · patients with hypertension
RAS inhibitors showed no clear difference in total myocardial infarction compared with beta‐blockers (low certainty).
1 finding from 1 review
Stroke · patients with hypertension
RAS inhibitors may leads to lower total stroke compared with beta‐blockers (low certainty).
1 finding from 1 review
Cardiovascular events · patients with hypertension
RAS inhibitors showed no clear difference in total cardiovascular events compared with CCBs (moderate certainty).
1 finding from 1 review
Death or hospitalization for heart failure · patients with hypertension
RAS inhibitors probably leads to lower death or hospitalization for heart failure compared with CCBs (moderate certainty).
1 finding from 1 review
Myocardial infarction · patients with hypertension
RAS inhibitors showed no clear difference in total myocardial infarction compared with CCBs (moderate certainty).
1 finding from 1 review
Stroke · patients with hypertension
RAS inhibitors probably leads to higher total stroke compared with CCBs (moderate certainty).
1 finding from 1 review
End‐stage renal disease · patients with hypertension
RAS inhibitors showed no clear difference in end stage renal failure compared with CCBs (low certainty).
1 finding from 1 review
All‐cause death · patients with hypertension
RAS inhibitors showed no clear difference in all‐cause death compared with thiazides (moderate certainty).
1 finding from 1 review
Cardiovascular events · patients with hypertension
RAS inhibitors showed no clear difference in total cardiovascular events compared with thiazides (moderate certainty).
1 finding from 1 review
Death or hospitalization for heart failure · patients with hypertension
RAS inhibitors probably leads to higher death or hospitalization for heart failure compared with thiazides (moderate certainty).
1 finding from 1 review
Change in SBP shortly after last session · people with primary hypertension
1 finding from 1 review
Change in DBP shortly after last session · people with primary hypertension
1 finding from 1 review
Intervention not reported
Adverse events · people with primary hypertension
1 finding from 1 review
Intervention not reported
LDL‐cholesterol fluvastatin 10 mg/day · participants with normal or abnormal lipid profiles
1 finding from 1 review
Intervention not reported
Total cholesterol fluvastatin 80 mg/day · participants with normal or abnormal lipid profiles
1 finding from 1 review
Intervention not reported
CI: Confidence interval · participants with normal or abnormal lipid profiles
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Mean baseline values. · participants with normal or abnormal lipid profiles
1 finding from 1 review
Intervention not reported
Triglycerides fluvastatin 10 mg/day · participants with normal or abnormal lipid profiles
1 finding from 1 review